Study describes changes in key Alzheimer's protein in humans
29 Aug 2008

Researchers have described hour-by-hour changes in the amount of a protein believed to play a key role in Alzheimer's disease in the human brain.

A collaborative study by staff at Washington University in St Louis, USA and the University of Milan, Italy, made their report on amyloid beta in the journal Science.

Levels of the protein were measured using microdialysis, with a small catheter placed into brain tissue to sample fluid in the spaces between cells.

A total of 18 patients recovering from ruptured brain aneurysms or traumatic brain injuries took part in the study.

It was found that recovery from brain injury, rather than the wound itself, seemed to cause an increase in amyloid beta levels, contradicting the expectations of the scientists.

Commenting on the results, co-first author Dr David Brody states: "Proving that we can directly measure amyloid beta in the human brain is an important step forward for both clinical and basic research and that may be true not just in Alzheimer's disease but also in other serious neurological disorders."

He concluded by noting that the researchers' ultimate goal is to develop interventions which can be applied after a traumatic brain injury to enhance outcomes and reduce long-term Alzheimer's risk.

Login and visit the Alzheimer's Disease Knowledge Centre

Print Article    Bookmark

• Blood sugar warning for the prevention of Alzheimer's 30/12/08
• Brain starvation seems to trigger Alzheimer's, study suggests 29/12/08
• Plans for new Alzheimer's clinics unveiled 24/12/08
• Cardiovascular proteins found to work together to speed up Alzheimer's 22/12/08
• Research looks at strategy games in the prevention of cognitive deterioration 12/12/08

• EBIXA 10mg film-coated tablets - 50.88%
  Treatment of patients with moderately severe to severe Alzheimers disease ...
  
  
• CERETEC - 26.56%
  ... the diagnosis of abnormalities of regional cerebral blood flow, such as those occurring following stroke and other cerebrovascular disease, epilepsy, Alzheimer's Disease and other forms of dementia, transient ischaemic attack, migraine and tumours of the brain. (ii) Technetium [99mTc] Exametazime ...
  
  
• EBIXA 10 mg/g oral drops, solution - 25.26%
  Treatment of patients with moderate to severe Alzheimer's disease ...
  
  
• EXELON Capsules - 25.26%
  Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease ...
  
  
• CEREZYME 400 U Solution for Infusion - 25.04%
  ... disease and who exhibit clinically significant non-neurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions: • anaemia after exclusion of other causes, such as iron deficiency • thrombocytopenia • bone disease ...
  
  
• CEREZYME 200 U Solution for Infusion - 25.04%
  ... disease and who exhibit clinically significant non-neurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions: • anaemia after exclusion of other causes, such as iron deficiency • thrombocytopenia • bone disease ...